Phase 1 cohort expansion study of LY3023414, a dual PI3K/mTOR inhibitor, in patients with advanced mesothelioma

BACKGROUND LY3023414 is a selective, ATP competitive inhibitor of class I PI3K isoforms, mTORC1/2 and DNA-PK. A Phase 1 dose escalation, 200 mg twice daily (BID) of LY3023414 was the determined recommended phase 2 dose (RP2D). We report the antitumor activity and safety of LY3023414 monotherapy in p...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:Invest New Drugs
Main Authors: Zauderer, Marjorie G., Alley, Evan W., Bendell, Johanna, Capelletto, Enrica, Bauer, Todd M., Callies, Sophie, Szpurka, Anna M., Kang, Suhyun, Willard, Melinda D., Wacheck, Volker, Varghese, Anna M.
Format: Artigo
Sprog:Inglês
Udgivet: Springer US 2021
Fag:
Phase I Studies
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC8280020/
https://ncbi.nlm.nih.gov/pubmed/33660194
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10637-021-01086-6
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker